Posted on 6/27/19
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline
STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the . . .
Posted on 6/27/19
Catalent Biologics To Acquire Novavax’ Manufacturing Assets and Capabilities
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases
Posted on 6/27/19
Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital
EWING, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has entered into an amendment to its existing loan . . .
Posted on 6/27/19
Merck Throws Its Hat Into The Ring With Keytruda For Treating Subset Of Lung Cancer Patients
SummaryMerck Announced FDA approval for Keytruda as a third-line therapy for patients with SCLC.SCLC accounts for about 10% to 15% of the entire lung cancer market.A . . .
Posted on 6/27/19
Johnson & Johnson Looks To Blood Cancer Drug Successor With Early-Stage Deal
SummaryJohnson & Johnson teams up again with Genmab, this time to bring a potential successor to Darzalex known as HexaBody-CD38.The reasoning for developing HexaBody-CD38 is to . . .
Posted on 6/27/19
TG Therapeutics: Hitting A Growth Inflection
SummaryDuring the past six months, TG Therapeutics is demonstrating the behavior of a bioscience stock operating at a growth inflection.TG will report Phase 3 data of . . .
Posted on 6/26/19
Delve Labs Closes Funding Round Led by 3dot6 Ventures and Desjardins Capital
Delve Labs, the pioneer in AI-based vulnerability management and prioritization, today announced they have secured additional funding. This round of financing was led by 3dot6 Ventures . . .
Posted on 6/26/19
The Medicines Company Prices Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of . . .
Posted on 6/26/19
Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical
Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has . . .
Posted on 6/25/19
AdhereHealth And Papa Partner to Tackle Barriers of Care
AdhereHealth™, a leading healthcare technology company focused on medication adherence, has announced a partnership with Papa, an award-winning companionship platform company serving the elderly, blind and . . .
Posted on 6/25/19
Avista Capital Partners To Sell Trimb To Karo Pharma
Avista Capital Partners, a leading private equity firm focused on growth-oriented healthcare businesses, today announced that Karo Pharma AB (publ),
Posted on 6/25/19
Intensity Therapeutics Announces Clinical Collaboration with Merck
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic . . .
Posted on 6/25/19
Pfizer: This Blue Chip DGI Name Strengthens Its Pipeline With Array BioPharma
SummaryPfizer is generally a fairly boring company.PFE shares offer a 3.4% dividend yield and relatively low volatility.On Monday, PFE management inked a $11.4b M&A deal that . . .
Posted on 6/25/19
Pfizer: Array Deal Makes Sense
SummaryPfizer will strengthen its oncology portfolio through the Array acquisition, expected to be completed in H2-2019.At $48/share, the all-cash deal will be financed by debt and . . .
Posted on 6/25/19
The Medicines Company Launches Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the . . .
Posted on 6/24/19
NanoVibronix Closes $3.2 Million Private Placement
ELMSFORD, N.Y., June 24, 2019 (GLOBE NEWSWIRE) -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which . . .
Posted on 6/24/19
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: CELG).
Posted on 6/24/19
AdvanSix Issues Statement Regarding Philadelphia Refinery Fire
PARSIPPANY, N.J.--(BUSINESS WIRE)--AdvanSix (NYSE: ASIX) said today that the Company is assessing the potential business impact of the fire that occurred Friday morning at the Philadelphia . . .
Posted on 6/24/19
Melinta Therapeutics: sNDA Acceptance Triggers 200% Gain
Summary Melinta Therapeutics stock rockets as a result of BAXDELA's sNDA being accepted by the FDA for a priority review. The company was given a PDUFA . . .
Posted on 6/21/19
bluebird bio: Returning To A Previous Winner
Summary bluebird bio's gene therapy, Zynteglo, gets the thumbs up on a conditional approval to treat patients with ß-thalassemia in the EU. However, it appears the . . .
Posted on 6/21/19
Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination
Summary Bristol-Myers Squibb announced its plan to acquire Celgene more than 6 months ago. The deal has since been approved by shareholders from both companies. Celgene . . .
Posted on 6/21/19
Is Pfizer Overpaying for Array Biopharma?
When Pfizer (NYSE:PFE) opened up its checkbook this week to buy Array Biopharma (NASDAQ:ARRY), it was bidding for a small cancer portfolio that has big potential. But . . .
Posted on 6/21/19
3 Drugs Under FDA Review With Blockbuster Potential
Being the first drugmaker to develop a therapy attacking a new target in cells can result in blockbuster sales. But other companies can wrestle that market . . .
Posted on 6/21/19
Northwell Opens Pancreatic Cancer Center
Approximately 60,000 new cases of pancreatic cancer are diagnosed each year in the US and less than 10 percent of those people will survive. Among the . . .
Posted on 6/20/19
Seven and Eight Biopharmaceuticals Announces Clinical Collaboration
EDISON, N.J.--(BUSINESS WIRE)--Seven and Eight Biopharmaceuticals Inc. today announced that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven . . .

